Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2018 - Key Players Involved & Drug Profiles Covered - ResearchAndMarkets.com
Jun. 11, 2018
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1).
The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects.
The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics.
Companies MentionedGlaxoSmithKline Plc Inovio Pharmaceuticals Inc Otsuka Holdings Co Ltd SELLAS Life Sciences Group Inc Sumitomo Dainippon Pharma Co Ltd Vaximm AG
Key Topics CoveredIntroduction Report Coverage Wilms Tumor Protein (WT33 or WT1) - Overview Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment Assessment by Route of Administration Assessment by Molecule Type Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/cfrvfv/wilms_tumor?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005832/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs ,Kidney Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 11:54 AM/DISC: 06/11/2018 11:54 AM